Walleye Capital LLC Purchases Shares of 18,425 AnaptysBio, Inc. $ANAB

Walleye Capital LLC purchased a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 18,425 shares of the biotechnology company’s stock, valued at approximately $1,022,000. Walleye Capital LLC owned about 0.06% of AnaptysBio at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of AnaptysBio by 4.5% during the 4th quarter. Vanguard Group Inc. now owns 1,544,037 shares of the biotechnology company’s stock worth $74,855,000 after purchasing an additional 67,048 shares during the period. State Street Corp raised its holdings in AnaptysBio by 20.6% in the fourth quarter. State Street Corp now owns 1,053,474 shares of the biotechnology company’s stock valued at $51,072,000 after buying an additional 180,042 shares during the period. 683 Capital Management LLC raised its holdings in AnaptysBio by 18.5% in the fourth quarter. 683 Capital Management LLC now owns 648,093 shares of the biotechnology company’s stock valued at $31,420,000 after buying an additional 101,093 shares during the period. Affinity Asset Advisors LLC acquired a new position in AnaptysBio during the fourth quarter valued at approximately $21,559,000. Finally, Goldman Sachs Group Inc. lifted its position in AnaptysBio by 20.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 398,914 shares of the biotechnology company’s stock valued at $19,339,000 after buying an additional 69,094 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on ANAB shares. HC Wainwright started coverage on shares of AnaptysBio in a research note on Wednesday, June 10th. They set a “buy” rating and a $95.00 price objective for the company. UBS Group lifted their target price on shares of AnaptysBio from $60.00 to $76.00 and gave the company a “buy” rating in a report on Wednesday, May 13th. Weiss Ratings cut shares of AnaptysBio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. Zacks Research downgraded AnaptysBio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 2nd. Finally, Wall Street Zen lowered AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Nine investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $82.00.

AnaptysBio Stock Down 1.4%

ANAB opened at $54.15 on Friday. The firm’s 50 day moving average is $58.38 and its 200-day moving average is $57.47. AnaptysBio, Inc. has a 52-week low of $11.40 and a 52-week high of $72.36. The firm has a market capitalization of $1.60 billion, a P/E ratio of -50.14 and a beta of 0.68.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($1.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($1.20). The business had revenue of $25.56 million for the quarter, compared to analysts’ expectations of $18.86 million. Equities analysts expect that AnaptysBio, Inc. will post -1.35 earnings per share for the current fiscal year.

AnaptysBio declared that its board has approved a stock buyback plan on Friday, March 27th that allows the company to buyback $100,000.00 billion in shares. This buyback authorization allows the biotechnology company to repurchase up to 5,352,316.2% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.

AnaptysBio Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.